NuCana (NCNA) Stock Price, News & Analysis

Company Overview

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure. NUC-3373 is being evaluated in multiple Phase 2 studies, including trials in colorectal and gastric cancers. In addition to NUC-3373, the company is advancing NUC-7738, an innate immune response modulator, through early-stage clinical development. These programs exemplify NuCana’s strategy of applying its ProTide chemistry to diversify treatment options for oncology patients.

Founded in 2013, NuCana has grown from a UK-based research startup into a globally oriented organization with clinical operations and collaborations across North America and Europe. Under the leadership of Chief Executive Officer Alastair Smith, the company continues to expand its clinical footprint, engaging with academic institutions and industry partners to accelerate the development and potential commercialization of its drug candidates. NuCana remains committed to translating its proprietary chemistry platform into differentiated therapies that address unmet medical needs in cancer care.

Key Stats

• Today's Range: $1.28 to $1.33
• 50-Day Range: $1.24 to $2.33
• 52-Week Range: $1.21 to $13.00
• Volume: 15,340 shs
• Average Volume: 54,216 shs
• Market Capitalization: $5.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

NuCana Stock Analysis - MarketRank™

NuCana scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

NuCana has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

NuCana has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NuCana is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NuCana is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NuCana has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.04% of the float of NuCana has been sold short.

Short Interest Ratio / Days to Cover

NuCana has a short interest ratio ("days to cover") of 2.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NuCana has recently decreased by 11.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NuCana does not currently pay a dividend.

Dividend Growth

NuCana does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

4 people have added NuCana to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NuCana insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 7/21/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NCNA
• CIK: 1709626
• Web: www.nucana.com
• Phone: 441313571111
• Fax: N/A
• Employees: 30
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($2.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -153.61%
• Return on Assets: -116.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.48
• Quick Ratio: 5.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.71 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 4,160,000
• Free Float: 2,863,000
• Market Cap: $5.37 million
• Optionable: Not Optionable
• Beta: 2.23